AZD3839 is primarily investigated for its potential application in the treatment of Alzheimer's disease. It functions as a beta-secretase (BACE1) inhibitor, targeting the enzyme responsible for the production of amyloid-beta peptides. By inhibiting BACE1, AZD3839 aims to reduce the accumulation of amyloid plaques in the brain, which are believed to play a key role in the progression of Alzheimer's. Its development focuses on slowing cognitive decline and improving neurological function in patients. Research and clinical trials are ongoing to evaluate its efficacy, safety, and therapeutic potential in managing this neurodegenerative disorder.